BioDuro LLC, a global life sciences contract research, development and manufacturing organization announced a cooperation agreement with Porton Pharma Solutions, Ltd., a leading provider of custom, cross life-cycle active pharmaceutical ingredient (API) development and cGMP manufacturing services to the global drug industry.
Under this agreement, BioDuro will promote and market Porton’s extensive and proven capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates, while Porton will incorporate BioDuro’s comprehensive array of unique technologies and expert resources in drug discovery, and BioDuro’s expert formulations development and cGMP manufacture of clinical trial materials into Porton’s suite of solutions to address complex process scale-up challenges for IND-enabling studies.
“Our partnership with Porton further expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical development,” said Cyrus K. Mirsaidi, BioDuro’s President and CEO.
Porton Pharma Solutions is a provider of custom Active Pharmaceutical Ingredient (API) development and manufacturing services to the global drug industry with cGMP production sites and marketing offices located across Asia, North America and Europe. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions was founded in 2005 and is headquartered in Chongqing, China